NasdaqGS:NVAXBiotechs
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus
Novavax (NasdaqGS:NVAX) has signed a licensing agreement with Pfizer covering the use of its Matrix-M adjuvant technology in up to two infectious disease areas.
The deal includes upfront payments to Novavax, with the potential for future milestone payments and royalties tied to Pfizer’s use of Matrix-M.
The agreement signals industry interest in Novavax’s adjuvant platform and introduces new potential revenue channels alongside its own vaccine programs.
For you as an investor, this puts...